Implantable defibrillators (ICDs) are the treahent of first choice concerning survived sudden cardiac death (SCDJ or symptomatic ventricular tachycardias (VT). 
Introduction
Implantable defibrillators (ICDs) are the treatment of first choice concerning survived sudden cardiac death (SCD) or symptomatic ventricular tachycardias (VT) [l] 121. The conventional Follow-Up Scheme in this ICDTherapy is normally provided as a doctor-visit every 3 to 6, partly 12 months. The frequency of extra visits depends on the patient's events and patients demands due to e.g. shocks /repeated episodical shocks.
During conventional physical Follow-Up normally the Collection and Analysis of Implant-Data is done, Tests with the Programming Device are performed and Pacemaker Configuration & Patient's Medication is changed if necessary -but in a defined portion of cases it turns out, that a doctor-visit wouldn't have been necessary [3] .
As shown in Figure 1 with the new Home Monitoring (HM) technology provided by Biotmnik Inc. [4] it is now possible to perform telemetric longdistance interrogations and controls including information about the system status and episodes detected and treated. This continuous remote monitoring of ICD therapy can monitor the incidence of tachy-and bradycardia episodes, the therapy success rate and the actual system status. HM can provide a continuous remote monitoring of medication therapy and anti-and pro-arrhythmic effects can be petformed. Therefore with HM it seems possible to do a better allocation of resources and provide even higher quality of care with additional economic impact. One may further expect a shortened reaction time to cardiac events and especially a reduction of unnecessary routine Follow-Up.
Objective of work
Target of the work was to bundle first results from a systematic clinical investigation (= Home-ICD Trial) and define a raw model for a multi-layer economic research on the question of the cost-effectiveness ratio of the treatment.
With this first raw model a general draft on the treatment's cost-effectiveness ratio should be developed. The model should picture the basic setting of HM and should allow easy integration of future data from clinical investigation.
Therefore a Markov-Chain Model with three abstracted types of complications and three layers of economic benefit seemed to be feasible for this task. The model allows future simulations with different clinical data drawn from tables for each single period of investigation. 
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Methods and results
The investigational device was a Biotronik Belos VR- Non-compliant Pts. 19
As shown in Table 1 since May 2002 228 patients with the given parameters (see Table 2 ) could be included in the trial. Indications for ICD implantation were: ventricular tachycardia (VT): n=l17 (a%), ventricular flutter (VF): n=55 (28%), VT and V F n=8 (4%) and other reasons: n=16 (8%).
In 19 Patients HM couldn't be started -14 days after release from hospital no HM message was received even after repeated requests. These Patients have been classified non-compliant and have been excluded from further investigations. After implantation implementation and testing of HM was performed. Routine interrogations and controls of ICD were performed 4 weeks and 3.6 and 9 months after surgery.
HM-interrogations and reports were delivered including information regarding battery status (battery), lead impedance (LI), shock impedance (SI), counts of episodes (VTNF) and therapies delivered (ATP (overdrive stimulations) shocks).
Overall 82% percent of the reports were received successfully. Table 3 shows the data on the HM successrate. 
Preliminary economic results
First results and preliminary studies on user acceptance and quality of life showed a very good acceptance and a highly significant increased feeling of security in the patients.
Preliminary Investigations on the use of a combined Fax I Intemetplatform for condensed view of historical and actual patient data show good doctor acceptance and a siginificant acceleration in clinical workflow and individual diseasemanagement.
Additionally special investigations were done on the necessity of a clinical Follow-Up. Basing on the HM data the doctor had to evaluate the necessity of the clinical visit, had to perform the physical visit and then had to decide, if the visit was necessary or not.
show a good concordance of doctors prediction on the Follow-Up necessity from the HM Data.
Further Investigations include the detailed calculation of this data including the time needed for the different types of investigation physical vs. telemetric.
First results
2.3.
Iba
The Markovmodel Figure 3 . View of the designed Markovmodel with collapsed subtrees and collapsed formulas. Figure 3 shows a partial view of the designed Markovmodel.
Basic principle is the (Monte Carlo) simulation of a sample number of patients running their way through the Model for a defined number of periods. Matrices behind each node can define the costs for the virtual patients on there different layers: Real procedural Costs, Cost for Payers (Soding) and Costdata on National Economic Scale (e.g. Costs for being absent from work or cost for travelling.)
For the different types of complications possibly occurring in the model, a simple abstraction was chosen: Type A are complications being able to be solved with HM, but lead to an unnecessary Follow-Up, Type B are complications getting worse just with HM, but being seen andlor hindered in a normal physical Follow-Up, Type C are complications with no preference for one of the two methods.
The Matrices-Based Approach is also chosen for the single possibilities to get in different states in each period. This way new or changing data can be integrated fast and easy.
Discussion
Home The first investigations show good feasibility for more in depth investigations on the investigation of the costsavings in different potential patient pathways depending on the Indication for ICD-Implantation. This will hopefully lead to enough data for the developed model to run valid simulations on cost-saving aspects.
At this point of time it seems like Home Monitoring enables seamless and automatic surveillance of ICD patients and Home Monitoring enables the physician to focus on patients needing more attention than others.
Principally through limitation of scheduled and unscheduled office visits, limitation of patient's time off from work and through a potential increase of quality adjusted lifetime the HM approach seems be good for a better Cost-Effectiveness Ratio of ICD-Treatment. Additionally the use of condensed view and reporting tools and the resulting close timeframe of monitoring allows better decisions on the necessity for masures to improve the patient's benefit from antiarrhythmic therapy and therefore potentially saves money by saving the patient from potential events depending on his individual indication.
The developed model allows easy stepby-step integration of data and can adapt fast to any changes and knowledge drawn hom the clinical HM setting in evaluation.
The developed model seams to be feasible for further data Integration and precision of data estimations.
As the system is capable of calculation with different cost matrices for costs in real, costs for payers and costs on national economic level it seems especially capable for payer-provider negotiations in a changing healthinsurance-reimbursement environment.
